

REPS2 (H-145): sc-98458

BACKGROUND

REPS2, a cytoplasmic protein, is primarily expressed in cerebellum, lung, testis, cerebrum and kidney. REPS2 forms as complex with DDEF1 and then binds to paxillin. It can also form a complex with activated RAL, which interacts with the Rho subfamily member Cdc42, and with Ral BP-1, which is involved in growth factor signaling via its influence on the RAL signaling pathway. The NFκB subunit p65 interacts with the EH domain of REPS2, and an upregulation of NFκB activity correlates with a downregulation of REPS2 activity. Decreased expression of REPS2 during progression cancer cells may lead to loss of control of growth factor signalling and thus, loss of control of cell proliferation. REPS2 may also be an important factor in cancer cell resistance to apoptosis.

REFERENCES

- Ikeda, M., Ishida, O., Hinoi, T., Kishida, S. and Kikuchi, A. 1998. Identification and characterization of a novel protein interacting with Ral-binding protein 1, a putative effector protein of Ral. *J. Biol. Chem.* 273: 814-821.
- Oshiro, T., Koyama, S., Sugiyama, S., Kondo, A., Onodera, Y., Asahara, T., Sabe, H. and Kikuchi, A. 2002. Interaction of POB1, a downstream molecule of small G protein Ral, with PAG2, a paxillin-binding protein, is involved in cell migration. *J. Biol. Chem.* 277: 38618-38626.
- Oosterhoff, J.K., Penninkhof, F., Brinkmann, A.O., Anton Grootegoed, J. and Blok, L.J. 2003. REPS2/POB1 is downregulated during human prostate cancer progression and inhibits growth factor signalling in prostate cancer cells. *Oncogene* 22: 2920-2925.
- Huang, K.M., Geunes-Boyer, S., Wu, S., Dutra, A., Favor, J. and Stambolian, D. 2004. Organization and annotation of the Xcat critical region: elimination of seven positional candidate genes. *Genomics* 83: 893-901.
- Penninkhof, F., Grootegoed, J.A. and Blok, L.J. 2004. Identification of REPS2 as a putative modulator of NFκB activity in prostate cancer cells. *Oncogene* 23: 5607-5615.
- Oosterhoff, J.K., Kühne L.C., Grootegoed J.A, Blok L.J. 2005. EGF signalling in prostate cancer cell lines is inhibited by a high expression level of the endocytosis protein REPS2. *Int. J. Cancer.* 113: 561-567.
- Sugiyama, S., Kishida, S., Chayama, K., Koyama, S. and Kikuchi, A. 2005. Ubiquitin-interacting motifs of Epsin are involved in the regulation of insulin-dependent endocytosis. *J. Biochem.* 137: 355-364.
- Yadav, S., Zajac, E., Singhal, S.S., Singhal, J., Drake, K., Awasthi, Y.C. and Awasthi, S. 2005. POB1 over-expression inhibits RLIP76-mediated transport of glutathione-conjugates, drugs and promotes apoptosis. *Biochem. Biophys. Res. Commun.* 328: 1003-1009.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

CHROMOSOMAL LOCATION

Genetic locus: REPS2 (human) mapping to Xp22.2; Reps2 (mouse) mapping to X F4.

SOURCE

REPS2 (H-145) is a rabbit polyclonal antibody raised against amino acids 141-285 mapping within an internal region of REPS2 of human origin.

PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

REPS2 (H-145) is recommended for detection of REPS2 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for REPS2 siRNA (h): sc-61454, REPS2 siRNA (m): sc-61455, REPS2 shRNA Plasmid (h): sc-61454-SH, REPS2 shRNA Plasmid (m): sc-61455-SH, REPS2 shRNA (h) Lentiviral Particles: sc-61454-V and REPS2 shRNA (m) Lentiviral Particles: sc-61455-V.

Molecular Weight of REPS2: 78 kDa.

Positive Controls: NIH/3T3 whole cell lysate: sc-2210.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use goat anti-rabbit IgG-HRP: sc-2004 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible goat anti-rabbit IgG-HRP: sc-2030 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use goat anti-rabbit IgG-FITC: sc-2012 (dilution range: 1:100-1:400) or goat anti-rabbit IgG-TR: sc-2780 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

RESEARCH USE

For research use only, not for use in diagnostic procedures.